126 related articles for article (PubMed ID: 9298356)
1. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
[TBL] [Abstract][Full Text] [Related]
2. The analytical performance of the Ciba Corning ACS:180 automated immunoassay system. A multicentre evaluation.
Römer M; Haeckel R; Capelli M; Rocipon J
Eur J Clin Chem Clin Biochem; 1994 May; 32(5):395-407. PubMed ID: 7522059
[TBL] [Abstract][Full Text] [Related]
3. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
4. External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser.
Molina R; Bonfrer J; Banfi G; Bugugnani MJ; Cornu F; Hannemann-Pohl K; Hubl W; Merz O; Bach M; Mack M
Clin Lab; 2000; 46(3-4):169-79. PubMed ID: 10791126
[TBL] [Abstract][Full Text] [Related]
5. A multicentre evaluation of the Ektachem DT60-, Reflotron- and Seralyzer III systems.
Römer M; Haeckel R; Henco A; Vogt M; Thomas L; Keller HE; Appel W
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):547-83. PubMed ID: 1457619
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.
Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352
[TBL] [Abstract][Full Text] [Related]
7. Multicentre evaluation of the Bayer DAX system.
Morosini L; Rossetti M; Berti P; Pallotti G; Fabbri V; Mambelli MC; Franceschin A; Dell'Anna L; Cappelletti P; Brocco G
Eur J Clin Chem Clin Biochem; 1993 Dec; 31(12):875-96. PubMed ID: 8136420
[TBL] [Abstract][Full Text] [Related]
8. Immunoassay of CEA, CA 19-9, CA 125, and CA 15-3 on the automated systems ES 300 and ES 600: methodological evaluation from a multicentre collaborative study.
Zucchelli GC; Pilo A; Jaworek D; Masini S; Chiesa MR
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):875-9. PubMed ID: 1489864
[TBL] [Abstract][Full Text] [Related]
9. Technical evaluation of three second generation CA 125 assays.
Bonfrer JM; Baan AW; Jansen E; Lentfer D; Kenemans P
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):201-7. PubMed ID: 8031969
[TBL] [Abstract][Full Text] [Related]
10. Multicentre tumour marker reference range study.
Wilson AP; Van Dalen A; Sibley PE; Kasper LA; Durham AP; el Shami AS
Anticancer Res; 1999; 19(4A):2749-52. PubMed ID: 10470234
[TBL] [Abstract][Full Text] [Related]
11. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three immunoassays for CA 19-9.
Hotakainen K; Tanner P; Alfthan H; Haglund C; Stenman UH
Clin Chim Acta; 2009 Feb; 400(1-2):123-7. PubMed ID: 19038241
[TBL] [Abstract][Full Text] [Related]
13. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
[TBL] [Abstract][Full Text] [Related]
14. Multicenter evaluation of the Elecsys CA 125 II assay.
Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
[TBL] [Abstract][Full Text] [Related]
15. Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new LOCI technique of Dimension Vista 1500 and Immulite 2000 XPI.
Zur B; Holdenrieder S; Albers E; Walgenbach-Brünagel G; Stoffel-Wagner B
J Immunoassay Immunochem; 2012; 33(4):435-45. PubMed ID: 22963492
[TBL] [Abstract][Full Text] [Related]
16. Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System.
van Helden J; Denoyel G; Karwowska S; Reamer R; Schmalz J; Wright T; Preisel-Simmons B
Clin Lab; 2004; 50(1-2):63-73. PubMed ID: 15000222
[TBL] [Abstract][Full Text] [Related]
17. Performance characteristics of seven automated CA 15-3 assays.
Slev PR; Rawlins ML; Roberts WL
Am J Clin Pathol; 2006 May; 125(5):752-7. PubMed ID: 16707378
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
19. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
[TBL] [Abstract][Full Text] [Related]
20. [Cryptates applied in tumor marker assays (CEA, AFP, CA 15.3, CA19.9): evaluation of Kryptor (Cis-Bio) analyser].
Gherardi C; Roumier AS; Dubucquoi S; Dessaint JP
Ann Biol Clin (Paris); 1998; 56(1):92-5. PubMed ID: 9754229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
